Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease

Neurotoxicity Research

Volumn 17, Issue 1, 2010, Pages 66-74

  Emerich, Dwaine F ^a   Mooney, David J ^b,c   Storrie, Hannah ^b   Babu, Rangasamy Suresh ^d   Kordower, Jeffrey H ^d  

^a Harvard University ^*  (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alginate; Huntington's disease; Hydrogel; Neuroprotection; VEGF

Indexed keywords

ALGINIC ACID; QUINOLINIC ACID; RECOMBINANT VASCULAR ENDOTHELIAL GROWTH FACTOR 165; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN 165; ENOLASE; NEUROPROTECTIVE AGENT; VASCULOTROPIN A;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG RESPONSE; FORELIMB; HUNTINGTON CHOREA; HYDROGEL; IMPLANTATION; MALE; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTACTIC PROCEDURE; SUSTAINED RELEASE PREPARATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEMISPHERIC DOMINANCE; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; SPRAGUE DAWLEY RAT; TIME;

ANIMALIA; RATTUS;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FUNCTIONAL LATERALITY; HUNTINGTON DISEASE; HYDROGELS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHOPYRUVATE HYDRATASE; PSYCHOMOTOR PERFORMANCE; QUINOLINIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77449104439     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9079-0     Document Type: Article

References (65)

1. Alberch J, Perez-Navarro E, Canals JM (2002) Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull 57:817-822
2. Alberch J, Perez-Navarro E, Canals JM (2004) Neurotrophic factors in Huntington's disease. Prog Brain Res 146:195-229
3. Araujo DM, Hilt D (1997) Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience 81:1099-1110
4. Araujo DM, Hilt DC (1998) Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience 82:117-127
5. Bloch J, Bachoud-Lévi AC, Déglon N, Lefaucheur JP,Winkel L, Palfi S, Nguyen JP, Bourdet C, Gaura V, Remy P, Brugiéres P, Boisse MF, Baudic S, Cesaro P, Hantraye P, Aebischer P, Peschanski M (2004) Neuroprotective gene therapy for Huntington's disease, using polymer encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968-975
6. Bogaert E, Van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, Scheveneels W, Robberecht W, Van Den Bosch L (2009) VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol. Aging Jan 28 epub
7. Cavalieri B (1966) Geometri degli indvisibli Tornio. Unione Tipografico, Editrice, pp 1-543
8. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH (2006) Nurr1 in Parkinson disease and related disorders. J Comp Neurol 494:495-514
9. Conneally PM, Wallace MR, Gusella JF, Wexler NS (1984) Huntington's disease: estimation of heterozygote status using linked genetic markers. Genet Epidemiol 1:81-88
10. Croll SD, Wiegand SJ (2001) Vascular growth factors in cerebral ischemia. Mol Neurobiol 23:121-135
11. Davies SW, Beardsall K (1992) Nerve growth factor selectively prevents excitotoxin-induced degeneration of striatal cholinergic neurones. Neurosci Lett 140:161-164
12. de Almeida LP, Zala D, Aebischer P, Deglon N (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8:P433-P446
13. Emerich DF (2001) Neuroprotective possibilities for Huntington's disease. Expert Opin Biol Ther 1:467-479
14. Emerich DF, Thanos CG (2006) Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa. Curr Gene Ther 6:147-159
15. Emerich DF, Winn SR, Lindner MD, Frydel BR, Kordower JH (1996) Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 16:5168-5181
16. Emerich DF, Winn SR, Chen EY, Chu Y, McDermott P, Baetge E, Kordower JH (1997) Protection of basal ganglia circuitry by encapsulated CNTF-producing cells in a primate model of Huntington's disease. Nature 386:395-399
17. Estrada Sanchez AM, Mejia-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 39:265-276
18. Fienberg AA, Greengard P (2000) The DARPP-32 knockout mouse. Brain Res Brain Res Rev 2:313-319
19. Ganhann FM, Popel AS (2008) Systems biology of vascular endothelial growth factors. Microcirculation 15:715-738
20. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk/KDR activation. J Biol Chem 273:30336-30343
21. Gratacos E, Perez-Navarro E, Tolosa E, Arenas E, Alberch J (2001) Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J Neurochem 78:1287-1296
22. Greenamyre JT, Shoulson I (1994) Huntington's disease. In: Calne D (ed) Neurodegenerative Diseases. Saunders Press, Inc., Philadelphia, pp 685-704
23. Greengard P (2001) The neurobiology of dopamine signaling. Biosci Rep 3:247-269
24. Gundersen H, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263
25. Hao X, Silva E, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Deligren G, Wardell E, Brodin LA, Mooney DJ, Sylven C (2007) Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 75:178-185
26. Jin KL, Mao XO, Nagayama T, Goldsmith PC, Greenberg DA (2000) Induction of vascular endothelial growth factor and hypoxia-inducible factor-1alpha by global ischemia in rat brain. Neuroscience 99:577-585
27. Jin K, Mao XO, Greenberg DA (2006) Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J Neurobiol 66:236-246
28. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Conor B (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a mouse model of Huntington disease. Mol Ther 9:682-688
29. Kordower JH, Isacson O, Emerich DF (1999) Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Exp Neurol 159:4-20
30. Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, Mufson EJ (2001) Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 49:202-213
31. Manoonkitiwongsa PS, Schultz RL, McCreery DB, Whitter EF, Lyden PD (2004) Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J Cereb Blood Flow Metab 24:693-702
32. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open label, phase I study. Lancet Neurol 7:400-408
33. Matsuzaki H, Tamatani M, Yamaguchi A, Namikawa K, Kiyama H, Vitek MP, Mitsuda N, Tohyama M (2001) FASEB J 15:1218-1220
34. McBride JL, During MJ, Wu J, Chen EY, Leurgans SE, Kordower JH (2003) Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 181:213-223
35. Menei P, Pean JM, Nerriere-Daguin V, Jollivet C, Brachet P, Benoit JP (2000) Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp Neurol 161:259-272
36. Mittoux V, Joseph JM, Conde F, Palfi S, Dautry C, Poyot T, Bloch J, Deglon N, Ouary S, Nimchinsky EA, Brouillet E, Hof PR, Peschanski M, Aebischer P, Hantraye P (2000) Restoration of cognitive and motor function with ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 11:1177-1187
37. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53-67
38. Perez-Navarro E, Arenas E, Reiriz J, Calvo N, Alberch J (1996) Glial cell line-derived neurotrophic factor protects striatal calbindin immunoreactive neurons from exitotoxic damage. Neuroscience 75:345-352
39. Perez-Navarro E, Arenas E, Marco S, Alberch J (1999) Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur J NeuroSci 11:241-249
40. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E (2000) Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem 75:2190-2199
41. Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD, Gasmi M, Bartus RT, Kordower JH (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis 3:40-50
42. Rosenstein JM, Krum JM (2004) New roles for VEGF in nervous tissue-beyond blood vessels. Exp Neurol 187:246-253
43. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiuama E, Kurihara T, Darland DC, Young MJ, D'Amore PA (2008) Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE 3:e3554
44. Sathasivam S (2008) VEGF and ALS. Neurosci Res 62:71-77
45. Schmitz C, Hof PR (2000) Recommendations of straightforward and rigorous methods of counting neurons based on a computer simulation approach. J Chem Neuroanat 20:93-114
46. Shoulson I (1981) Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31:1333-1335
47. Silva EA, Mooney DJ (2007) Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5:590-598
48. Silverman WF, Krum JM, Mani N, Rosenstein JM (1999) Vascular, glial, and neuronal effects of vascular endothelial growth factor in mesencephalic explants cultures. Neuroscience 90:1529-1541
49. Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor stimulates Schwaan cell invasion and neovascularization of acellular nerve grafts. Brain Res 846:219-228
50. Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26:943-954
51. Sun FY, Guo X (2005) Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J Neurosci Res 79:180-184
52. Svensson B, Peters M, Konig HG, Poppe M, Levkau B, Rothermundt M, Arolt V, Kogel D, Prehn JH (2002) Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspase-independent mechanism. J Cereb Blood Flow Metab 22:1170-1175
53. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-978
54. Tian Y, Tang CJ, Wang JN, Feng XW, Wang L, Qiao X, Sun SG (2007) Favorable effects of VEGF gene transfer on a rat model of Parkinsons disease using adeno-associated viral vectors. Neurosci Lett 421:239-244
55. Tolosa L, Mir M, Asensio VJ, Olmos G, Llado J (2008) Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem 105:1080-1090
56. Tovar-Y-Romo LB, Zepeda A, Tapia R (2007) Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J Neuropathol Exper Neurol 66:913-922
57. Vezzani A (2008) VEGF as a target for neuroprotection. Epilepsy Curr 8:135-137
58. Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA, Jin K (2007) Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis. J Neurosci 27:304-307
59. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497
60. West MJ, Ostergaard K, Andreassen OA, Finsen B (1996) Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J Comp Neurol 370:11-22
61. Wick A, Wick W, Walternberger J, Weller M, Dichgans J, Schulz JB (2002) Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J. Neuroscience 22:6401-6407
62. Yasuhara T, Date I (2007) Intracerebral transplantation of genetically engineered cells for Parkinsons disease: toward clinical application. Cell Transpl 16:125-132
63. Yasuhara T, Shingo T, Kobayashi K, Takeuchi A, Yano A, Muraoka K, Matsui T, Miyoshi Y, Hamada H, Date I (2004) Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parksinson's disease. Eur J NeuroSci 19:1494-1504
64. Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, Hayase H, Hamada H, Borlongan CV, Date I (2005) Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 1053:10-18
65. Zurn AD, Henry H, Schluep M, Aubert V, Winkel L, Eilers B, Bachmann C, Aebischer P (2000) Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant 9:471-484